Product Introduction:
This product adopts advanced small-molecule directed differentiation technology to efficiently convert human induced pluripotent stem cells (iPSCs) into mesenchymal-like stem cells (MSCs) with therapeutic potential. Through precise regulation of the differentiation process, the obtained mesenchymal-like stem cells (iPSC-MSCs) are highly similar to primary MSCs in terms of gene expression profile, surface marker characteristics, and multi-directional differentiation potential. Specifically, they continuously and stably express mesenchymal stromal cell markers such as CD90, CD73, and CD105, do not express non-specific markers such as CD45, CD34, and HLA, and maintain the tri-lineage differentiation potential of osteogenesis, adipogenesis, and chondrogenesis. Long-term passage verification shows that iPSC-MSCs exhibit excellent genomic stability without accumulation of chromosomal abnormalities.